NMSO 3

Drug Profile

NMSO 3

Alternative Names: NMSO3

Latest Information Update: 10 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fukushima Medical University; Nissin Food Products
  • Developer Fukushima Medical University; Microbiotix; Nissin Food Products; University of Texas Medical Branch
  • Class Antivirals; Lipids; Sulfates
  • Mechanism of Action CD4 antigen inhibitors; Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections; Metapneumovirus infections; Rotavirus infections

Most Recent Events

  • 10 Oct 2012 No development reported - Preclinical for HIV infections in Japan (unspecified route)
  • 10 Oct 2012 No development reported - Preclinical for Metapneumovirus-infections in USA (Intranasal)
  • 10 Oct 2012 No development reported - Preclinical for Rotavirus infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top